Germany to end free pricing for patented medicines
This article was originally published in Scrip
Germany's health ministry is planning to introduce compulsory price negotiations for patented drugs between the pharmaceutical industry and health insurers, it confirmed to Scrip. The measure could eventually put an end to free pricing in Europe's largest pharmaceutical market.
You may also be interested in...
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.